Sentences with phrase «for oncology research»

The Georgia Center for Oncology Research and Education (Georgia CORE) is an independent, non-profit organization led by a voluntary Board of Directors whose mission is to improve the quality of cancer care in Georgia by strengthening clinical research.

The Georgia Center for Oncology Research and Education (Georgia CORE), received a multi-tiered award from the Patient - Centered Outcomes Research Institute (PCORI) to support «Patient - Centered Cancer Survivorship Care: Improving Quality of Care and Quality of Life for Survivors in Georgia.»

nter for Oncology Research and Education (Georgia CORE), received a multi-tiered award from the Patient - Centered Outcom

Based on interviews and focus groups conducted across the state, a business plan was developed for the Georgia Center for Oncology Research and Education.

Panelists Margaret Offermann, MD, PhD (Bio) Vice President Elect for Science Policy Board of Directors at FASEB Treasurer and Member, Board of Directors at George Center for Oncology Research and Education

A unique, searchable online cancer information center, GeorgiaCancerInfo.org was created by the Georgia Center for Oncology Research and Education (Georgia CORE).

General Product Information Obesity - High Fat Diets for Diet - Induced Obesity Models Metabolic Syndrome - Diet - Induced Metabolic Syndrome in Rodent Models Diabetes - High Fructose / Sucrose Diets for inducing Hypertriglyceridemia and Insulin Resistance in Rodents Atherosclerosis - Diet - Induced Atherosclerosis / Hypercholesterolemia in Rodent Models Hypertension - Phenotypic Expression of Hypertension in Rodent Models through Dietary Manipulation NAFLD (Non-alcoholic Fatty Liver Disease) Cancer - Creating a Clean Background for Oncology Research Test Compounds / Kaolin Pellets Diet and Immunology Focus: Arsenic in Grain - Based Laboratory Animal Diets and Effects on the Rodent Toxicological Phenotype Focus: The Importance of a Proper Control Diet

He is the first Associate Director for Oncology Research in the Institute for Pharmacogenomics and Individualized Therapy.

Copyright © 2005 - 2018 Georgia Center for Oncology Research and Education, Inc..

Previously described as the «guardian of the genome» and voted «Molecule of the Year» in 1993, p53 is one of the most important proteins regulating cell growth and a major focus for oncology research.

Not exact matches

More news on the GBM front: Tomorrow (Thursday) and Friday, the Parker Institute for Cancer Immunotherapy, is hosting a glioblastoma immuno - oncology research summit in Los Angeles — bringing together top industry and academic scientists to share their research.

While Canadian biotechnology expatriates are the focus of this initiative, FACIT continues to attract worldwide leaders in oncology research to the province, a shared mandate well established by its strategic partner, the Ontario Institute for Cancer Researchresearch to the province, a shared mandate well established by its strategic partner, the Ontario Institute for Cancer ResearchResearch (OICR).

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

Hearing about the lipid biochemistry research from the Babraham Institute team and realising how we could translate its potential from an oncology perspective was a great moment for all of us!»

Much current research in immuno - oncology focuses on improving these treatments, for example, by finding new immunotherapy targets and identifying biomarkers that predict a patient's response.

She is now a director in Exploratory Immuno - Oncology at the Novartis Institutes for BioMedical Research (NIBR), where she relies on her basic research bacResearch (NIBR), where she relies on her basic research bacresearch background.

TCGA data, which has been the foundation of many immuno - oncology hypotheses and discoveries, will still be available for research.

We have estimated that up to 15 percent of patients will be candidates for dose optimization,» explained senior study author Javier F.Torres - Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRFor men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRfor extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRfor Radiation Oncology (ASTRO).

Professor Paolo Boffetta (MD), the Annals of Oncology associate editor for epidemiology and Director of the Institute of Translational Epidemiology at the Icahn School of Medicine at Mount Sinai in New York (USA), commented: «These results are extremely important in showing that reducing cancer mortality can be achieved: priority should be given to research in cancers with unfavourable trends, such as pancreatic cancer, and in reducing cancer mortality disparities, both between countries (Central / Eastern versus Western Europe), and within countries, for example, between socioeconomic groups.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Mresearch are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;

The study was led by Dr. Alexandre Zlotta, Director of Uro - Oncology at Mount Sinai Hospital, and researcher with the Lunenfeld - Tanenbaum Research Institute, part of Sinai Health System in Toronto, Canada, and Dr. Paul Boutros, Principal Investigator, Informatics and Bio-computing, Ontario Institute for Cancer Research (OICR).

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

Beyond its $ 100 - millionper - year platform research, Moderna runs four wholly owned ventures focused on drugs for infectious diseases, rare diseases, immuno - oncology, and personalized cancer vaccines.

She worked with Ganz for 3 years as a junior scientist, learning about cancer and chronic disease and charting a course in the relatively new field of psycho - oncology before applying for her own research funding.

To that end, Khanna created the Comparative Oncology Program within NCI's Center for Cancer Research.

She left Virtual Text in 2001 when she was offered a communications role at the Hutchison / MRC Research Centre in Cambridge, U.K., a research institute that aims to bridge basic research with oncology, where she and her scientist husband had applied for jobs in pResearch Centre in Cambridge, U.K., a research institute that aims to bridge basic research with oncology, where she and her scientist husband had applied for jobs in presearch institute that aims to bridge basic research with oncology, where she and her scientist husband had applied for jobs in presearch with oncology, where she and her scientist husband had applied for jobs in parallel.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

«This work is an example of how integrating basic science and clinical care may reveal privileged opportunities for biomedical research,» said Matthew O. Hebb, M.D., Ph.D., FRCSC, a researcher involved in the work from the Departments of Clinical Neurological Sciences (Neurosurgery), Oncology and Otolaryngology at the University of Western Ontario in Ontario, Canada.

Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening program to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.

Swiss Bridge Award for Research in Cancer Funding for basic cancer research, genetics and epidemiology, psycho - oncology and prevention research (total support approximating CHF 5Research in Cancer Funding for basic cancer research, genetics and epidemiology, psycho - oncology and prevention research (total support approximating CHF 5research, genetics and epidemiology, psycho - oncology and prevention research (total support approximating CHF 5research (total support approximating CHF 500,000).

Connecting a global network of more than 40,000 cancer professionals, the society serves as the leading resource for best practices in clinical oncology research and academic and community practices.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

Principal investigator E. Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.

Funding from the NIH / National Cancer Institute (grant CA135096), the American Cancer Society; The Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research, and The Sloman Foundation supported this rResearch, and The Sloman Foundation supported this researchresearch.

«While e-cigarettes may reduce smoking rates and attendant adverse health risks, we will not know for sure until these products are researched and regulated,» said Peter Paul Yu, president of the 35,000 - member American Society of Clinical Oncology, in a statement.

Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine and co-Leader of the Cancer Epigenetics Program at the Fox Chase Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.

In addition, Sandeep Koshy, Ph.D., who worked as a Graduate Student on Mooney's team and now is an Immuno - oncology Researcher at the Novartis Institutes for BioMedical Research in Cambridge, Mass., is an author on the study.

His research focuses predominantly on oncology molecular diagnostics, particularly the source and utility of miRNA biomarkers in blood, and the development of innovative molecular diagnostics for the identification of mutations that can guide therapeutic decision - making.

Research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 used a newly designed test for K: B fusion to show that point mutations lead to a more dangerous form of the disease than does K: B fusion.

«The link between metabolism and cancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Division.

«Even before the patient completes all of the MRIs, CT scans and other imaging procedures following diagnosis, we can have a recommendation for which drug and dosage to prescribe,» said Kareem Azab, PhD, an assistant professor of radiation oncology at the School of Medicine and the Siteman Cancer Center member who leads the research.

«AML is a disease in which fewer than 30 percent of patients are cured,» said co-senior author Ulrich Steidl, M.D., Ph.D., associate professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at MonResearch at Einstein and associate chair for translational research in oncology at Monresearch in oncology at Montefiore.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image - guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

Professor Tim Maughan, Clinical Director of the Cancer Research UK / Medical Research Council Oxford Institute for Radiation Oncology, said «This novel and exciting finding provides a new scientific basis for precision targeting of some cancers which are currently very difficult to treat, and we are now taking these findings into clinical trials.»